Condition
Pituitary Macroadenoma
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Terminated2
Enrolling By Invitation1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07712328Phase 4Enrolling By Invitation
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
NCT02396810Not ApplicableTerminatedPrimary
Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas
NCT04212793Phase 1Completed
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
NCT01444209Phase 2TerminatedPrimary
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
Showing all 4 trials